Endo-Impax settlement procompetitive, eased access to generic Opana ER, judge rules
A settlement by Endo Pharmaceuticals with Impax Laboratories didn't violate antitrust law because “the evidence proves that the Endo-Impax Settlement was, on balance, procompetitive,” a judge ruled on Friday in dismissing...
Subscription required to view this article.
This content can only be accessed by FTCWatch subscribers. If you are an FTCWatch subscriber, please login to access this content
If you do not currently subscribe to FTCWatch please contact us for subscription information: